

National Jewish Statement on Singulair Investigation

DECEMBER 03, 2008

DENVER — The U.S. Food and Drug Administration (FDA) recently announced that it is investigating a possible link between the use of the asthma and allergy medication Singulair (montelukast) and behavior or mood changes, including suicidal thinking and action.

The investigation is based upon a small number of reported suicides among millions of people who have taken Singulair. None of the more than 40 studies of Singulair involving more than 11,000 adults and children have reported a link between Singulair and suicidal thoughts or actions. Each year more than 32,000 people in the United States commit suicide. The FDA investigation is expected to take up to nine months to complete. Until then, no one can be sure if there is any link between Singulair and suicide.

In the meantime, physicians at National Jewish recommend that patients taking Singulair, and the related medications Accolate, Zyflo, and Zyflo CR, should continue taking those medications as long as they are effective and the patient does not experience any suicidal behavior or thoughts.

Patients who experience significant behavior or mood changes, especially signs of depression or thoughts of suicide, should consult their physicians immediately to discuss whether to continue taking the medication.

Additional resources:

[FDA Statement on Singulair Investigation](#)

[Joint Statement from the American Academy of Allergy Asthma & Immunology and the American College of Allergy Asthma & Immunology](#)

[Statement from Singulair manufacturer, Merck & Co., Inc.](#)

National Jewish Health is the leading respiratory hospital in the nation. Founded 121 years ago as a nonprofit hospital, National Jewish Health today is the only facility in the world dedicated exclusively to groundbreaking medical research and treatment of patients with respiratory, cardiac, immune and related disorders. Patients and families come to National Jewish Health from around the world to receive cutting-edge, comprehensive, coordinated care. To learn more, visit the [media resources page](#).

Media Contacts

Our team is available to arrange interviews, discuss events and story ideas.

William Allstetter
303.398.1002
allstetterw@njhealth.org

Adam Dormuth
303.398.1082
dormutha@njhealth.org